Article

FDA Grants Orphan Drug Designation to PCLX-001 for AML

Author(s):

The FDA has granted an orphan drug designation to PCLX-001 for the treatment of patients with acute myeloid leukemia.

The FDA has granted an orphan drug designation (ODD) to PCLX-001 (DDD86481) for the treatment of patients with acute myeloid leukemia (AML).1

PCLX-001 is a first-in-class N-myristoylation (NMT) inhibitor that is currently being studied in non-Hodgkin lymphoma (NHL) and solid tumors at 4 sites in Canada as part of a phase 1 trial (NCT04836195). An investigational new drug application has also been filed to study PCLX-001 in patients with AML in the United States.

“The 5-year survival rate for AML patients 20 and older is only 27%. Patients relapse despite existing therapies. We are developing a first-in-class therapy that tackles AML in a new way that has been very effective in disease models and may be synergistic with other approaches,” Michael Weickert, PhD, president and chief executive officer of Pacylex, stated in a press release. “Our trial will offer relapsed patients another option. This ODD for PCLX-001 recognizes the importance of this potential new therapy for these patients.”

Preclinical models showed that PCLX-001 monotherapy generated complete remissions in subcutaneous AML cell line–derived xenografts. Additionally, PCLX-001 elicited up to 95% reduction of human peripheral blood and bone marrow CD45+ cells, which include the malignant stem cell population responsible for disease relapse, in tail vein–injected, AML patient–derived xenografts.

The planned study evaluating PCLX-001 in patients with AML will be the first to examine an NMT inhibitor as a treatment for the disease.

The ongoing phase 1 trial is investigating PCLX-001 monotherapy in patients with histologically confirmed advanced solid tumors who have failed at least one prior therapy and/or are not eligible for therapies expected to provide clinical benefit, or histologically confirmed B-cell lymphomas that are expected to express CD20, including diffuse large B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma (grades I to IIIB), mantle cell lymphoma, and Burkitt lymphoma who have failed at least two prior therapies and/or are not eligible for therapies expected to provide clinical benefit (including autologous stem cell transplantation).2

The trial is comprised of two parts, including single-agent dose escalation in part A and single-agent expansion cohorts in part B. In part A, the trial will follow a 3+3 design. If no dose-limiting toxicities are observed in 3 patients at a dose level, 3 more patients will be treated at the next dose level. Patients will receive oral PCLX-001 daily as part of a 28-day cycle, and the starting dose of PCLX-001 will be 20 mg daily. After the maximum tolerated dose (MTD) is defined in part A, patients in part B will receive the MTD.

“Our ongoing clinical trial in [patients] with NHL and solid tumors showed PCLX-001 was well-tolerated and achieved drug exposures likely to benefit [patients with] AML,” John Mackey, MD, chief medical officer of Pacylex, stated in a press release. “We look forward to treating AML patients with PCLX-001 in the near future.”

References

  1. Pacylex announces orphan drug designation granted to PCLX-001 for the treatment of acute myeloid leukemia. News release. Pacylex. October 14, 2022. Accessed October 17, 2022. https://bit.ly/3MBqK70
  2. Phase I trial of PCLX-001 in B-cell non-Hodgkin lymphoma and advanced solid malignancies. ClinicalTrials.gov. Updated September 27, 2022. Accessed October 17, 2022. https://clinicaltrials.gov/ct2/show/NCT04836195
Related Videos
Minoo Battiwalla, MD, MS, director, Blood Cancer Outcomes Research, Sarah Cannon Research Institute, TriStar Medical Group
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Shyam A. Patel, MD, PhD
Amitkumar Mehta, MD
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Jean L. Koff, MD, MS
Sonali M. Smith, MD